# A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

> **NCT05967351** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 400 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **GENETIC:** delandistrogene moxeparvovec

## Key facts

- **NCT ID:** NCT05967351
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-09-27
- **Primary completion:** 2033-10-31
- **Final completion:** 2033-10-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05967351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05967351, "A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05967351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*